Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma
Clinical trial NCT07584733 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07584733
- Sponsor
- RenJi Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-31
- Primary completion
- 2027-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.